Ianevski Aleksandr, Yao Rouan, Simonsen Ronja M, Myhre Vegard, Ravlo Erlend, Kaynova Gerda D, Zusinaite Eva, White Judith M, Polyak Stephen J, Oksenych Valentyn, Windisch Marc P, Pan Qiuwei, Lastauskienė Eglė, Vitkauskienė Astra, Matukevičius Algimantas, Tenson Tanel, Bjørås Magnar, Kainov Denis E
Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway.
Vilnius Ozo Gymnasium, Vilnius University, Vilnius 07171, Lithuania.
iScience. 2022 Mar 17;25(4):104112. doi: 10.1016/j.isci.2022.104112. eCollection 2022 Apr 15.
Broadly effective antiviral therapies must be developed to be ready for clinical trials, which should begin soon after the emergence of new life-threatening viruses. Here, we pave the way towards this goal by reviewing conserved druggable virus-host interactions, mechanisms of action, immunomodulatory properties of available broad-spectrum antivirals (BSAs), routes of BSA delivery, and interactions of BSAs with other antivirals. Based on the review, we concluded that the range of indications of BSAs can be expanded, and new pan- and cross-viral mono- and combinational therapies can be developed. We have also developed a new scoring algorithm that can help identify the most promising few of the thousands of potential BSAs and BSA-containing drug cocktails (BCCs) to prioritize their development during the critical period between the identification of a new virus and the development of virus-specific vaccines, drugs, and therapeutic antibodies.
必须开发出具有广泛疗效的抗病毒疗法，以便为临床试验做好准备，一旦出现新的危及生命的病毒，临床试验应尽快启动。在此，我们通过综述保守的可靶向药物的病毒-宿主相互作用、作用机制、现有广谱抗病毒药物（BSA）的免疫调节特性、BSA的给药途径以及BSA与其他抗病毒药物的相互作用，为实现这一目标铺平道路。基于该综述，我们得出结论，BSA的适应症范围可以扩大，并且可以开发新的泛病毒和跨病毒单药及联合疗法。我们还开发了一种新的评分算法，该算法可以帮助从数千种潜在的BSA和含BSA的药物组合（BCC）中识别出最有前景的几种，以便在识别新病毒与开发病毒特异性疫苗、药物和治疗性抗体的关键时期，对它们的开发进行优先级排序。
